SEARCH

SEARCH BY CITATION

References

  • 1
    Parry SD., Stansfield R, Jelley D et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98: 19705.
  • 2
    Parry SD, Stansfield R, Jelley D et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003; 98: 32731.
    Direct Link:
  • 3
    Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 38996.
  • 4
    Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 30411.
  • 5
    Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 91320.
  • 6
    Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 177883.
  • 7
    Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 16519.
  • 8
    Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 157883.
    Direct Link:
  • 9
    Dunlop SP, Jenkins D, Neal KR et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 7784.
  • 10
    Öhman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and integrin beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 9806.
  • 11
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 80411.
  • 12
    Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53: 145964.
  • 13
    Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol 2005; 40: 8007.
  • 14
    Zar S, Benson MJ, Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 15507.
    Direct Link:
  • 15
    Zuo XL, Li YQ, Li WJ et al. Alterations of food antigen-specific serum immunoglobulins G and E antibodies in patients with irritable bowel syndrome and functional dyspepsia. Clin Exp Allergy 2007; 37: 82330.
  • 16
    Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005; 238: 6775.
  • 17
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II437.
  • 18
    Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52: 16239.
  • 19
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395402.
  • 20
    Öhman L, Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007; 39: 20115.
  • 21
    Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 8028.
  • 22
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 35036.
    Direct Link:
  • 23
    Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 18025.
  • 24
    Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 37382.
    Direct Link:
  • 25
    Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004; 21: 40113.
  • 26
    Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 6118.
  • 27
    Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3: 93951.
  • 28
    Öhman L, Lindmark A-C, Isaksson S et al. Dysfunctional T cell responses after polyclonal stimulation in patients with irritable bowel syndrome (IBS). Gastroenterology 2008; 134: A41.
  • 29
    Simrén M, Månsson A, Langkilde AM et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 10815.